Adalimumab Biosimilar Market Overview

Ajouter une nouvelle offre d'emploi Health

2026-06-26 09:32:29 -

The Adalimumab Biosimilar Market was valued at USD 3.75 billion in 2024 and is projected to reach USD 15 billion by 2035, growing at a CAGR of 13.4%. Adalimumab biosimilars offer cost-effective alternatives to the reference biologic Humira, treating autoimmune conditions including rheumatoid arthritis, Crohn's disease, psoriasis, and ulcerative colitis. The market is segmented by therapeutic...

0 Commentaires 0 Parts 64 Vue 0 Aperçu